Mankind Pharma Limited has informed the Exchange about Acquisition
MANKIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Mankind Pharma reported audited standalone revenue of ₹10,421 Crores for FY2026, up 9.6% from ₹9,507 Crores in FY2025. Profit after tax stood at ₹713.61 Crores with basic EPS of ₹17.29. The Board approved additional investment of up to ₹500 Crores in its wholly-owned subsidiary Mankind Medicare Private Limited. Executive Directors (Chairman, Vice Chairman & MD, and CEO) voluntarily waived their commission for FY2025-26 to strengthen the company's cash position for business expansion. The Board also reappointed Mr. Satish Kumar Sharma as Whole-Time Director for 5 years and approved Cost Auditor reappointment.
Strong financial performance with 9.6% revenue growth and profit expansion indicates healthy operational performance. The ₹500 Crore investment in subsidiary signals continued expansion plans while executive commission waiver reflects management confidence in future growth.